Lineage Cell Therapeutics explores future of dry AMD treatment

Lineage Cell Therapeutics explores future of dry AMD treatment
@LineageCell: Lineage explores dry AMD future

Lineage Cell Therapeutics took part in the insightful discussions at the Ocular Innovations Summit in San Diego.

CEO Brian Culley participated in a panel focusing on the future outlook of dry age-related macular degeneration (AMD), assessing whether it constitutes one disease or several multifaceted conditions.

Moderated by Dr. Emmett T. Cunningham Jr., the panel addressed the complexities and the innovative directions in treating dry AMD, emphasizing the impact of emerging research and treatment strategies. Culley, alongside other experts, shared forward-looking perspectives and considered the various paths the medical field might pursue to tackle this challenging vision issue.

The strategic direction outlined by Lineage Cell Therapeutics at the summit aligns with its broader commitment to regenerative medicine, as seen in the company’s development of scalable allogeneic cell therapies to restore function. These advancements, coupled with forthcoming corporate disclosures such as the upcoming Q3 2025 results and business update call, underscore the organization's ongoing efforts to translate scientific progress into meaningful outcomes for patients confronting degenerative eye diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.